R.E.C.K vs Exparel in Robotic Nephrectomy

The purpose of the study is to evaluate the efficacy of R.E.C.K (ropivacaine epinephrine clonidine ketorolac) vs Exparel during robotic partial and radical nephrectomy in a single institution, prospective, randomized trial. The study will evaluate post operative Numerical Rating Score (NRS) pain scores, post operative pain medication intake (opioids and over-the-counter pain medicines) and length of stay across the two patient cohorts. The findings will help to inform whether the increased cost of Exparel when compared to R.E.C.K is justified.

NCT Number	NCT07092566
Lead Sponsor	Wake Forest University Health Sciences Collaborators: Atrium Health Levine Cancer Institute
Conditions	Renal Carcinoma, Nephrectomy / Methods, Pain Management
Enrollment	170 participants
Start Date	2025-11-14
Primary Completion	2027-10 (estimated)
Study Completion	2027-10 (estimated)
Updated on ClinicalTrials.gov	2026-07-13